Clinic Roundup

Keryx Biopharmaceuticals Inc., of New York, disclosed the final dataset from its Phase III short-term trial of Zerenex (ferric citrate) in hyperphosphatemia in end-stage renal disease patients on dialysis, with data showing changes in mean serum phosphorus of -2.0 mg/dL for the 6-g dose group and -2.2 mg/dL for the 8-g group, both with a "p" value of less than 0.0001. Additional data showed a dose response in serum bicarbonate, suggesting the potential to address metabolic acidosis, and a statistically significant dose response reduction in calcium x phosphorus product.